ADDENDUM: CANCER CARE OUTCOMES RESEARCH AND SURVEILLANCE CONSORTIUM (RFA-CA-01-013) Release Date: October 4, 2000 NOTICE: CA-01-001 National Cancer Institute This addendum is to inform potential applicants of three changes to RFA-CA-01- 013 entitled “Cancer Care Outcomes Research and Surveillance Consortium” released August 24, 2000. First, a change with regard to minimum enrollment for each Primary Data Collection and Research (PDCR) site applicant is as follows: 1. Under SPECIAL REQUIREMENTS, Terms and Conditions of Award, Part B, Primary Data Collection and Research (PDCR) site responsibilities, the minimum number of patients is changed from 1,000 to 700 patients per cancer (lung and colorectal). 2. Under APPLICATION PROCEDURES, Specific Instructions for PDCR sites, instruction number 2, the minimum number of patients to be enrolled is changed from 1,000 to 700 patients per cancer over a two year accrual period. As before, applicants are not required to participate in studies of both lung and colorectal cancer. 3. Under REVIEW CONSIDERATIONS, Specific Review Criteria: PDCR Sites, number 2a, the minimum number of cases is changed from 1,000 per cancer type to 700 per cancer type. Second, given the reduction of the minimum sample size allowed, all PDCR site applicants are encouraged to target 1,000 patients per cancer type, if resources permit, in order to achieve the sample size objective of 6,000 patients per cancer within the CanCORS Consortium as a whole. The third change is a clarification of the definition of the Principal Investigator under the section entitled RESEARCH OBJECTIVES, Definitions. Currently, the definition reads: “Each institution may have more than one CanCORS PI, and a single person may be the PI for an application that includes both lung and colorectal cancer.” The revised statement reads: “Since there must be a single PI for each application, one person will be the PI for those applications that include both lung and colorectal cancer. On such applications, the PI may designate a second individual to be a full participating member of the CanCORS Steering Committee.” All other provisions of CA-01-013 remain unchanged. The complete RFA can be found at http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-01-013.html INQUIRIES Inquiries are encouraged, and the opportunity to clarify issues and answer questions is welcome. Inquiries may be directed to: Arnold L. Potosky, Ph.D. Division of Cancer Control and Population Sciences National Cancer Institute 6130 Executive Boulevard, Room 4005, MSC 7344 Bethesda, MD 20892-7344 Telephone: (301) 496-5662 FAX: (301) 435-3710 Email: potosky@nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |